Valuation: NovoCure Limited

Market Cap 1.94B 1.69B 1.6B 1.45B 2.72B 186B 2.73B 19.17B 7.4B 94.81B 7.3B 7.14B 305B P/E 2026 *
-13.3x
P/E 2027 * -20.4x
Enterprise Value 1.84B 1.6B 1.51B 1.37B 2.57B 176B 2.59B 18.13B 7B 89.67B 6.9B 6.75B 289B EV / Sales 2026 *
2.53x
EV / Sales 2027 * 2.15x
Free-Float
90.04%
Yield 2026 *
-
Yield 2027 * -
1 week+8.92%
Current month-3.47%
1 month-2.41%
3 months-6.32%
6 months+39.15%
Current year+31.50%
1 week 13.2
Extreme 13.2
14.72
1 month 13
Extreme 13.005
15.72
3 years 8.26
Extreme 8.264
32.77
5 years 8.26
Extreme 8.264
117
Manager TitleAgeSince
Chief Executive Officer 46 30/11/2025
Director of Finance/CFO 52 31/12/2024
Chief Tech/Sci/R&D Officer - 16/01/2023
Director TitleAgeSince
Director/Board Member 59 31/12/2011
Chairman 63 31/12/2008
Director/Board Member 64 04/08/2011
Change 5-day change 1-year change 3-year change Capi.($)
+0.41%+8.92%+33.61%-17.36% 1.94B
-0.40%-0.04%+23.22%+21.11% 12.51B
-1.05%+0.77%+11.94%+16.93% 6.52B
-1.09%-3.16% - - 6.12B
-0.21%+2.66%+23.70%+10.27% 5.54B
-1.53%-1.17%-20.99%+35.65% 4.99B
+0.38%+3.39%-31.74%-24.86% 3.9B
-0.18%+7.61%+28.38%-11.32% 1.94B
-1.65%-2.30%-18.13%+191.44% 1.71B
-1.95%+2.06%+45.86%-17.74% 1.57B
Average -0.85%+0.78%+10.65%+22.68% 4.98B
Weighted average by Cap. -0.72%+0.18%+10.65%+18.62%

Financials

2026 *2027 *
Net sales 726M 633M 598M 543M 1.02B 69.65B 1.02B 7.16B 2.76B 35.41B 2.73B 2.67B 114B 805M 702M 663M 602M 1.13B 77.22B 1.13B 7.94B 3.06B 39.26B 3.02B 2.96B 126B
Net income -142M -124M -117M -106M -199M -13.63B -200M -1.4B -541M -6.93B -534M -522M -22.29B -84.78M -73.93M -69.81M -63.39M -119M -8.14B -119M -836M -323M -4.14B -318M -311M -13.31B
Net Debt -105M -91.98M -86.85M -78.86M -148M -10.12B -148M -1.04B -401M -5.15B -396M -387M -16.56B -210M -183M -173M -157M -294M -20.14B -295M -2.07B -799M -10.24B -789M -771M -32.95B
Logo NovoCure Limited
NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
Employees
-
Date Price Change
18/09/26 €14.59 +0.41%
17/09/26 €14.53 +2.90%
16/09/26 €14.12 +1.29%
15/09/26 €13.94 +0.11%
14/09/26 €13.93 +3.96%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
16.69USD
Average target price
27.14USD
Spread / Average Target
+62.63%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!